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Abstract
Background: Postoperative pain prevention is essential for the recovery of surgical patients. Continuous (thoracic)
epidural analgesia (CEA) is routinely practiced for major abdominal surgery, but evidence is conflicting on its benefits
in this setting. Potential disadvantages of epidural analgesia are a) perioperative hypotension, frequently requiring
additional intravenous fluid boluses or prolonged use of vasopressors; b) relatively high failure rates, with periods of
inadequate analgesia; and c) the risk of rare but serious, at times persistent, neurologic complications (hematoma and
abscess). In recent years, continuous (subfascial) wound infiltration (CWI) plus patient-controlled analgesia (PCA) has
been suggested as a safe and reliable alternative, which does not have the previously mentioned disadvantages, but
evidence from multicenter trials targeting a specific surgical population is lacking. We hypothesize that CWI+PCA is
equally as effective as CEA, without the mentioned disadvantages.
Methods/design: POP-UP is a randomized controlled noninferiority multicenter trial, recruiting adult patients
scheduled for elective hepato-pancreato-biliary surgery via laparotomy in an enhanced recovery setting. A total of 102
patients are being randomly allocated to CWI+PCA or (P)CEA. Our primary endpoint is the Overall Benefit of Analgesic
Score (OBAS), a composite endpoint of pain intensity, opioid-related adverse effects and patient satisfaction, during
postoperative days 1 to 5. Secondary endpoints include length of the hospital stay, number of patients with severe
pain, and the use of rescue medication.
Discussion: POP-UP is a pragmatic trial that will provide evidence of whether CWI+PCA is noninferior as compared to
(P)CEA after elective hepato-pancreato-biliary surgery via laparotomy in an enhanced recovery setting. If this hypothesis
is confirmed, this finding could contribute to more widespread implementation of this technique, especially when the
described disadvantages of epidural analgesia are less often observed with CWI+PCA.
Trial registration: Netherlands Trial Register NTR4948 (registry date 2 January 2015).
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Background
Postoperative pain prevention is essential for the recov-
ery of surgical patients. Effective analgesia may prevent
complications such as pneumonia, thromboembolic
events, and anxiety among patients. Effective analgesia
can facilitate early mobilization and hence may result in
earlier recovery [1].
Continuous (thoracic) epidural analgesia (CEA) is
routinely practiced for pain prevention after elective
laparotomy, including hepato-pancreato-biliary (HPB)
surgery. This is supported by a recent Cochrane review,
which showed statistically but not clinically relevant better
analgesia with CEA compared to patient-controlled intra-
venous analgesia (PCA) alone [2, 3]. Although CEA is
sometimes promoted as part of fast-track or enhanced-
recovery programs [4], evidence is conflicting on its bene-
fits in this setting [5]. Potential disadvantages of CEA in-
clude a) perioperative hypotension, frequently requiring
additional intravenous fluid boluses with risk of hypervo-
lemia or prolonged use of vasopressors; b) relatively high
failure rates (up to 30 % [6, 7]), with periods of
inadequate analgesia; c) the risk of rare but serious
and sometimes persistent neurologic complications
(hematoma and abscess)(approximately 1 in 5,700 for
thoracic epidurals in surgical patients) [8]; and d) the
need for indwelling urinary catheters. For these rea-
sons, alternatives have been explored.
Patient-controlled epidural analgesia (PCEA) is rapidly
gaining ground. The perceived benefits of PCEA com-
pared to CEA are lower incidences of motor block,
smaller infused volume of local anesthetic, and patients
being less likely to require unscheduled anesthetic inter-
vention [9]. Not all have switched, however, because
PCEA and CEA have a similar safety profile, and ran-
domized trials are lacking.
A promising alternative for (P)CEA is continuous
(subfascial) wound infiltration (CWI) plus PCA. In sev-
eral high volume centers for hepato-pancreato-biliary
surgery, CWI+PCA has become the routine analgesic
approach for all laparotomies. CWI involves the place-
ment of two to three percutaneous catheters by the
surgeon prior to closing of the laparotomy in the preper-
itoneal space. Continuous infusion of local anesthetics is
started via these catheters. This technique potentially
lacks the described downsides of (P)CEA. One of the
disadvantages of CWI is potentially inferior pain control
during the first 24 h requiring PCA with subsequent
short-term higher opiate use [10]. Furthermore, CWI
+PCA requires the use of two to three extra infusion
pumps per patient.
The only randomized controlled trial with hospital stay
as primary endpoint concluded that patients fulfilled the
discharge criteria faster with the use of wound infiltra-
tion compared to epidural analgesia [11].
Although various studies have shown promising re-
sults of CWI+PCA [10, 11], a widespread implementa-
tion of this technique has not yet been realized. One of
the reasons could be the lack of randomized controlled
trials, especially trials that focus on specific subsets of
abdominal surgical procedures. This study focusses
specifically on hepato-pancreato-biliary surgery.
Objectives
To test the hypothesis that CWI+PCA is noninferior in
terms of OBAS compared to (P)CEA for patients undergo-
ing elective hepato-pancreato-biliary surgery via laparot-
omy with fewer side effects compared to (P)CEA.
Trial design
This trial is designed as a randomized controlled, paral-
lel group, open-label, noninferiority, multicenter trial.
Methods/design
Study design
This is an investigator-initiated randomized controlled
noninferiority multicenter trial. The study is being per-
formed in accordance with the Declaration of Helsinki
(Fortaleza, Brazil, October 2013) and has been approved by
the ethics committee of the Academic Medical Center
(AMC) Amsterdam (METC Academisch Medisch Cen-
trum Amsterdam, reference MEC2014_329). Secondary
approval was obtained from the board of the Onze Lieve
Vrouwe Gasthuis (OLVG) teaching hospital Amsterdam,
according to the Dutch Centrale Commissie Mensgebon-
den Onderzoek (CCMO) External Review Directive 2012
(Richtlijn Externe Toetsing 2012).
Both departments of surgery cooperate regarding
hepato-pancreato-biliary surgery within the GastroIntes-
tinal Oncologic Center Amsterdam (GIOCA). Patients
are informed about the study on their visit to the out-
patient clinic. Afterward, the study coordinator contacts
them and provides them the patient information sheet
and obtained written informed consent.
Inclusion/exclusion criteria
Inclusion criteria are as follows: (1) 18 years and older,
(2) elective hepato-pancreato-biliary surgery via laparot-
omy, and (3) written informed consent.
Exclusion criteria are as follows: (1) ASA status ≥ 4,
(2) chronic opioid use (>1 year), (3) renal or liver fail-
ure, (4) contraindication for epidural analgesia, (5) al-
lergy to study medication, (6) International Normalized
Ratio (INR) > 1.5, Partial Thromboplastin Time (PPT) >
1.5, and platelets < 80.
Randomization
Patients are randomized centrally by the study co-
ordinator using an online randomization module
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(sealedenvelope.com) in a 1:1 ratio between CWI+PCA
and (P)CEA. Randomization is stratified by center and by
type of laparotomy (that is, subcostal or midline) to bal-
ance differences in general treatment regimens. Blinding
of the patient and caregivers is considered infeasible given
the obvious differences between the methods (for ex-
ample, preoperative placement of the epidural). The block
size is subject to random variation and concealed to all in-
vestigators involved in the study.
Intervention plan
All patients are treated within an enhanced recovery
program. This program consists of (1) preoperative
nutritional optimization, (2) absence of preoperative
fasting, (3) antithrombotic prophylaxis, (4) early removal
of the nasogastric tube, (5) avoiding hypothermia, (6)
optimal glycemic control, (7) no drain or early drain re-
moval, (8) maintaining a near-zero fluid balance and




Intraoperative Immediately after laparotomy, the sur-
geon injects two to three boluses (depending on the type
of laparotomy) of 10 ml bupivacaine 0.25 % in the space
between peritoneum and posterior fascia at the locations
where the two to three CWI catheters are placed at the
end of the procedure. At the end of the procedure,
wound catheters (standard 18G epidural catheter, REF
4513150, B. Braun Medical, Melsungen, Germany) are
placed by the surgeon in the pre-peritoneal space: three
in case of a right or left subcostal incision and two in
case of a midline laparotomy.
Catheter positions, all in the pre-peritoneal space (see Fig. 1)
at the same location in which the boluses were placed at
the beginning of the procedure are indicated:
1. Catheter right subcostal region, tunneled via the
rectus sheath to the skin.
2. Subcostal under the right rectus muscle sheath,
tunneled via the rectus sheath to the skin, exiting
close to catheter 1. Catheters 1 and 2 are joined at
the filter and stabilized with an adhesive pad.
(Statlock, REF IV0621CE, Bard Medical,
Nieuwegein, the Netherlands).
3. Subcostal under the left rectus muscle sheath,
tunneled via the rectus sheath to the skin, rolled and
stabilized with an adhesive pad (Statlock, see 2).
After placement, each catheter is infused with a bolus
of 10 ml bupivacaine 0.25 % (total 30 ml).
Postoperative
The three catheters are each connected to an infusion
pump with bupivacaine 0.125 % at 4 ml/hr. In cases of a
midline laparotomy, only catheter positions 2 and 3 are
used. In this case both run at 6 ml/h of bupivacaine
0.125 %. The maximum combined infusion rate is
12 ml/h over 24 h. The maximum dose of bupivacaine is
0.25 ml/kg. The PCA contains morphine (1 mg bolus
with a 5-min lockout). The 4-h maximum dose is 30 ml,
equaling 30 mg morphine.
Control arm: (P)CEA
Perioperative
Preoperatively, an anesthesiologist places an epidural
catheter at the Th 7 to 8 level. The epidural catheter is
used during surgery. The epidural solution consists of
bupivacaine (0.125 %) and sufentanil (1 μg/ml). After ini-
tial failure of an epidural placement, a maximum of
three additional attempts are made. If this fails, this is
considered a pre-operative failed epidural, and these pa-
tients are then treated according to the intervention arm
in order to provide adequate pain management.
Postoperative
When the treatments are administered continuously at
6 ml/h, patients are able to receive a bolus of 2 ml with
a lockout time of 20 min. The 4-h maximum was set at
1.2 mg bupivacaine/kg. In case of a non-patient-
controlled epidural (site: OLVG Amsterdam), continuous
infusion of a solution (consisting of bupivacaine 0.125 %
and sufentanil 0.5 μg/ml) is started (0.1 ml/kg/h).
When CEA or PCEA does not provide adequate pain
relief, minor adjustments or a manual top-up are
allowed. This is counted as requiring specialist supervi-
sion (see Table 1).
Adherence to intervention protocols
Participation of patients is communicated to all involved
surgery and anesthesiology staff the day before surgery.
The implementation of the intervention is followed up
by the study coordinator regularly to ensure adherence
to the study protocol. Data are checked for completion.
General treatment regimen
Pre-operative
During the study, patients receive standard preoperative
care. In addition, induction of anesthesia, blood pressure
management, and mechanical ventilation are standard of
care and similar between groups.
Perioperative
Induction of anesthesia
In the operating room, general anesthesia is induced
with 2 to 3 mg·kg-1 propofol (Fresenius Kabi, Zeist,
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the Netherlands), sufentanil (Bipharma, Almere, the
Netherlands) for analgesia and 0.6 mg·kg-1 rocuronium
(Fresenius Kabi, Zeist, the Netherlands) for paralysis. The
trachea is intubated, and the lungs are mechanically venti-
lated with pressure regulated volume control. After induc-
tion, general anesthesia is maintained with sevoflurane
(AbbVie, Hoofddorp, the Netherlands) at a minimal alveo-
lar concentration (MAC) of 1 and, when needed (based on
signs of pain), is supplemented by an additional bolus of
sufentanil. An arterial line is inserted into the right
or left radial artery. A right jugular tri-lumen central
line is inserted when deemed necessary. A double
lumen gastric cannula is inserted. A urinary catheter is
inserted. Cefazoline (Kefzol™) 2 g and metronidazol
(Flagyl™) 500 mg are given prior to incision. Cefazoline is
repeated after 6 h if the surgery is ongoing.
Fig. 1 POP-UP flowchart. ASA: american society of anesthesiologists, CWI: continuous wound infiltration, PCA: patientcontrolled analgesia,
P(CEA): (patient-controlled) continuous epidural analgesia, INR: internation normalized ratio, PPT: partial thromboplastin time, CRF: case
report form
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Analgesia
Besides sufentanil, further analgesia is at the discre-
tion of the anesthesiologist and according to local
protocols, which include the use of fentanyl, lidocaine,
and ketanest.
Fluid management
Fluid management is done primarily according to stroke
volume (SV), stroke volume variation (SVV), or pulse
pressure variation (PPV) guided, goal-directed fluid ther-
apy (GDFT) protocol [12]. SV, cardiac index (CI), PPV/
SVV and systemic vascular resistance (SVR) are ob-
tained by means of FloTrac (Edwards Lifesciences) or
esophagus Doppler monitoring (EDM).
Post-operative
Besides the intervention, patients receive the standard
pain treatment with paracetamol (four times 1 g) and
metamizol (start with 2 g, followed by four times 1 g, to
a maximum of 4 g per day) or naproxen (twice daily
250 mg) (unless contraindicated).
Patients receive a daily visit from the Acute Pain Ser-
vice (APS), as is a standard of care. The APS team scores
the OBAS daily and adjusts the analgesia if necessary. A
tentative stop of CWI or (P)CEA is planned on day 3
when feasible and earlier when possible. The APS sys-
tematically screens for side effects (for example, monitor
sedation levels and puncture sites).
Rescue medication
If analgesia remains inadequate (NRS > 4) after the
maximum adjustments possible within the interven-
tion arm, rescue medication is allowed. This is ac-
cording to local protocols and includes morphine,
piritramide and ketanest.
Primary endpoint
The primary outcome of this study is the Overall Benefit
of Analgesic score (OBAS) (See Fig. 2). The OBAS is
a multidimensional quality assessment instrument to
measure patients’ benefits from postoperative pain
therapy. OBAS is a validated score combining pain
score, patient satisfaction and opioid-related side ef-
fects [13].
Secondary endpoints
Secondary endpoints include the total operative time
(recorded as total time spent in the operating room,
anesthetic time, surgical time); length of hospital stay;
failure of analgesic technique; pain every 12 h until dis-
charge at rest and movement (VAS scores); cumulative
opioid consumption; additional analgesic consumption;
days CWI/PCEA needed; and side effects up to 30 days,
including hypotension with the need for additional fluid
boluses during and after surgery and norepinephrine
dependency. Both at the end of surgery and at the end
of the PACU stay, we record the following: 1) duration
of norepinephrine requirement and cumulative con-
sumption, 2) fluid boluses administered and 3) fluid bal-
ance. The prolonged postanesthesia care unit (PACU)/
intensive care unit (ICU) stay; duration of indwelling
urinary catheter drainage per day; pruritus; postoperative
nausea and vomiting; and complications related to
anesthetic technique, such as central nervous system
(CNS) toxicity, epidural hematoma, epidural abscess,
post-surgical pain (after 30 days, 6 months and 12 months)
and analgesics dependency. Technical complications (see
Table 2 for definitions) include the following: the failure of
analgesic technique, need for rescue medication, and need
for specialist intervention.
Summary of known and potential risks and benefits
Potential risks of CWI are the need for rescue anal-
gesia, abdominal wound infection and CNS toxicity.
Compared to other local anesthetics, bupivacaine is
markedly cardiotoxic [14]. However, adverse drug re-
actions (ADRs) are rare when the bupivacaine is ad-
ministered correctly.
Data analysis
The primary analysis will be per protocol. Secondary
analyses will include an intention-to-treat analysis. Base-
line characteristics will be presented using descriptive
statistics. Continuous data will be assessed using a
Student’s t-test if they are normally distributed or a
Mann Whitney U test if otherwise. Categorical data will
be analyzed using a Chi-square test or Fisher exact test.
The mean difference between the two groups will be
presented together with the higher bound of the 90 %
confidence interval. If, in the per-protocol analysis, the
higher bound of the 90 % confidence interval is lower
Table 1 Definitions of technical complications
Failure of placement Failure of placement (continuous wound infiltration/epidural)
Catheter failure Catheter dislodgement, migration or leakage, leading to premature removal
Need for rescue medication Patients remain painful (NRS* > 4) after maximum adjustments possible within the intervention arm
Need for specialist intervention Suboptimal functioning on ward leading to supervision by an anesthesiologist and/or minor adjustments
*NRS: numeric rating scale
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than +3 OBAS point difference and the 90 % confidence
interval does not include the inferiority limit, noninferi-
ority is considered proven. Additionally, the difference
between the two groups will be assessed with a one-
sided Student’s t-test or a Mann Whitney U test, as
appropriate.
Data on the primary and secondary endpoints that are
missing will be categorized as no event. For other ana-
lyses, data will be considered missing at random. A sen-
sitivity analysis excluding non-patient-controlled-CEA
will be performed.
Sample size
A difference in a mean OBAS score of less than three
points is considered noninferior. Therefore, the study
must have the power to detect a difference of three
points to reject the null hypothesis that CWI is inferior
compared to (P)CEA. Using a one-sided alpha of 0.05, a
standard deviation of 5 and a power of 90 %, 48 patients
are necessary in each group. With an expected loss to
follow up of 5 %, the total number of patients to
randomize is 102. We aim to complete inclusion
within a 12-month period because we have a recruit-
ment pool of 180 laparotomies for hepato-pancreato-
biliary conditions per year in both centers combined
and expect 60 % of the patients to be both eligible
and willing to participate.
Descriptive statistics
For dichotomous data, frequencies will be presented.
Continuous data will be presented as mean and standard
deviation or median and interquartile range. Baseline
characteristics (all prior to randomization) are as follows:
age, sex, body mass index (BMI), American Society of
Anesthesiologists (ASA) physical status, smoking/non-
smoking, indication for surgery, type of surgery/incision,
preoperative pain (as VAS) and use of analgesics.
Dissemination policy
The trial’s results will be submitted to a peer-reviewed
journal regardless of the outcome.
Discussion
Benefits
Both CEA and CWI+PCA have been described as effect-
ive methods to provide postoperative analgesia after
midline or subcostal laparotomy [5, 10, 15] but (P)CEA
is current routine practice in most centers worldwide.
We hypothesize that the use of CWI+PCA is noninferior
to CEA as measured by OBAS and has fewer potential
disadvantages than described for CEA. In our opinion,
the OBAS score is superior to VAS for evaluating the
true effectiveness of analgesic therapy because OBAS is
a composite endpoint combining pain score, opiate side
effects and patient satisfaction [13]. This is unlike all
other previous studies, which focused primarily on pain
Table 2 Overall Benefit of Analgesic Score calculation sheet
[13]. Answers to the following statements are requested from
the patient
1. Please rate your current pain at rest on a scale between (0 =minimal
pain and 4 =maximum imaginable pain)
2. Please grade any distress and bother from vomiting in the past 24 h
(0 = not at all to 4 = very much)
3. Please grade any distress and bother from itching in the past 24 h
(0 = not at all to 4 = very much)
4. Please grade any distress and bother from sweating in the past 24 h
(0 = not at all to 4 = very much)
5. Please grade any distress and bother from freezing in the past 24 h
(0 = not at all to 4 = very much)
6. Please grade any distress and bother from dizziness in the past 24 h
(0 = not at all to 4 = very much)
7. How satisfied are you with your pain treatment during the past 24 h
(0 = not at all to 4 = very much)
*To calculate the OBAS score, compute the sum of scores in items 1–6 and
add “4 − score in item 7”
Overall benefit of analgesia score* |__|__|
Fig. 2 Schematic overview of the location of the CWI catheters in case of subcostal (panel a) and midline incision (panel b)
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scores or cumulative opioid consumption. These end-
points are also collected in this study.
A recent large retrospective study suggested equivalent
pain scores and a reduced cumulative opioid consump-
tion with the use of the exact same method [10]. Besides
that, in a systematic review, different variants of the
method have proven to provide a similar analgesic effect
compared to CEA measured by pain scores on a visual
analog scale [15].
A secondary benefit of CWI+PCA is the broader field
of application outside this clinical trial. The technique
can be applied in patients with anticoagulant therapy,
coagulopathies, and after refusal of epidural analgesia. It
may also be used when laparoscopy is converted to
laparotomy and in case of emergency surgery. CWI
appears to be less invasive in nature and safer because of
the absent risk of epidural hematoma and abscess. The
placement under general anesthesia can be considered
an advantage as well as a disadvantage. When not
functioning, replacement is not possible outside the
operating room, but an epidural analgesic technique
would be possible in that case. Earlier removal of the
indwelling urine catheter is possible because there is
no additional risk of urinary retention [15]. CWI
could require less supervision on the ward by the
medical staff [16], although this is heavily dependent
on the local situation.
In contrast to other trials, where relatively expensive
wound catheters were used that had costs sometimes as
much as 280 euro per device [17], the extra cost of the
materials used in our study is around 50 euro per
patient. This is because we use the standard three-hole
epidural catheter instead of the various variations of
wound catheters with up to eight or sixteen holes. Since
the location is subfascial, diffusion through the whole
preperitoneal space is hypothetically possible; therefore,
we do not expect advantages with the use of catheters
with more side holes. This hypothesis is in line with the
results of the previous mentioned retrospective study
where the three-hole catheters as well as the same loca-
tion were used [10]. Our study is the first randomized
trial to focus on practice-related benefits like hospital
stay, indwelling urinary catheter use, hypotension,
PACU/ICU stay and post-surgical pain as well as long-
term analgesia dependency.
Limitations
This is an open-label study. Since patient satisfaction is
an important parameter for the OBAS, this design could
be of influence. However, since our goal is to pragmatic-
ally investigate the entire effect of both treatment strat-
egies and because patients are not blinded in daily
practice and multiple placebo catheters (that is, CWI)
might influence patient satisfaction, this might be of
preference [18]. We chose noninferiority because super-
iority is not likely to be achieved for the primary out-
come parameter. Furthermore, superiority was not
considered necessary because of the previously men-
tioned advantages of CWI+PCA. A limitation of the
study is that the patients in one center are treated with
non-patient controlled CEA instead of PCEA. We expect
this to apply to 20 to 25 % of all recruited patients. A
benefit is that we can compare these groups afterwards.
A sensitivity analysis will be performed regarding non-
patient controlled CEA. One might argue that the
addition of PCA to CWI is not necessary. However, pre-
vious studies have demonstrated that pain control in the
first 24 h after surgery is less with CWI [10], and pa-
tients presumably benefit in particular at that time from
PCA. In contrast to other studies, we added an add-
itional bolus at the start of the procedure (the bupiva-
caine bolus of 30 ml total immediately after laparotomy
on the final catheter sites). This is meant to compensate
for the perioperative use of the epidural that might be
the reason for the reduced pain control in the first 24 h.
The solution of the epidural consists of local anesthetic
combined with an opiate and CWI only provides a local
anesthetic. Due to a shortage of morphine receptors in
the abdominal layers, the local effect would be negligible
and is therefore not indicated in CWI [19]. Therefore,
the addition of opiates though PCA might be seen as lo-
gical. Another option was to opt for a more pure model
by removing sufentanil from the epidural in the control
group and also to equip them with PCA. However, be-
cause of the pragmatic approach of our trial, as well as
our preference to treat the control group according to
our current best practice, we chose not to remove
sufentanil.
Trial status
The first patient was randomized on 20 January 2015
with planned completion in February 2016. As of 20 July
2015, 71 of 102 patients (70 %) have been randomized,
and inclusion is progressing according to schedule.
Abbreviations
APS: acute pain service; CEA: continuous (thoracic) epidural analgesia;
CWI: continuous (subfascial) wound infiltration; ICU: intensive care unit;
OBAS: overall benefit of analgesic score; PACU: postanesthesia care unit;
PCA: patient-controlled analgesia; PCEA: patient-controlled epidural analgesia;
POP-UP: Continuous wound infiltration or epidural analgesia for pain
prevention after hepato-pancreato-biliary surgery within an enhanced recov-
ery program.
Competing interests
The authors TM, MB, DV, PL, MH, OB, TvG, SvD, TK, SdC, MG, and BT declare
that they have no competing interests.
Authors’ contributions
TM, MB, DV and PL drafted the protocol. TM, MB, DV, PL, MH, OB, TvG, SvD,
TK, SdC, MG, and BT participated in the design of the study during several
Mungroop et al. Trials  (2015) 16:562 Page 7 of 8
meetings. TM, MB, and SvD performed the sample size calculation. All
authors read and approved the final manuscript.
Acknowledgements
We acknowledge the Hepato-Pancreato-Biliary surgery and anesthesiology
team at University Hospital Southampton NHS Foundation Trust for demon-
strating their technique of CWI+PCA. This study is solely funded by institu-
tional/departmental sources. Primary sponsor: Academic Medical Center,
Amsterdam. (postal address: PO box 22660, 1100 DD Amsterdam, the
Netherlands)
Public title: Pain prevention after liver, pancreas, and biliary operations:
wound catheters or epidural analgesia. The POP-UP study.
Author details
1Department of Surgery, Academic Medical Center, University of Amsterdam,
Meibergdreef 9, Postbus 22660, 1100 DD, Amsterdam, The Netherlands.
2Department of Anesthesiology, Academic Medical Center, University of
Amsterdam, Meibergdreef 9, Postbus 226601100DD, Amsterdam, The
Netherlands. 3Department of Surgery, Onze Lieve Vrouwe Gasthuis,
Oosterpark 9, 1091AC, Amsterdam, The Netherlands. 4Department of
Anesthesiology, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091AC,
Amsterdam, The Netherlands.
Received: 22 July 2015 Accepted: 23 November 2015
References
1. Liu SS, Carpenter RL, Mackey DC, Thirlby RC, Rupp SM, Shine TS, et al.
Effects of perioperative analgesic technique on rate of recovery after colon
surgery. Anesthesiology. 1995;83:757–65.
2. Werawatganon T, Charuluxananan S. WITHDRAWN: Patient controlled
intravenous opioid analgesia versus continuous epidural analgesia for pain
after intra-abdominal surgery. Cochrane Database Syst Rev. 2013;3:
Cd004088.
3. Kehlet H, Wilkinson RC, Fischer HB, Camu F. PROSPECT: evidence-based,
procedure-specific postoperative pain management. Best Pract Res Clin
Anaesthesiol. 2007;21:149–59.
4. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome.
Am J Surg. 2002;183:630–41.
5. Hughes MJ, Ventham NT, McNally S, Harrison E, Wigmore S. Analgesia after
open abdominal surgery in the setting of enhanced recovery surgery: a
systematic review and meta-analysis. JAMA Surg. 2014;149:1224–30.
6. McLeod G, Davies H, Munnoch N, Bannister J, MacRae W. Postoperative pain
relief using thoracic epidural analgesia: outstanding success and
disappointing failures. Anaesthesia. 2001;56:75–81.
7. Ready LB. Acute pain: lessons learned from 25,000 patients. Reg Anesth Pain
Med. 1999;24:499–505.
8. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central
neuraxial blockades in Sweden 1990-1999. Anesthesiology. 2004;101:950–9.
9. van der Vyver M, Halpern S, Joseph G. Patient-controlled epidural analgesia
versus continuous infusion for labour analgesia: a meta-analysis. Br J
Anaesth. 2002;89:459–65.
10. Wong-Lun-Hing EM, van Dam RM, Welsh FK, Wells JK, John TG, Cresswell
AB, et al. Postoperative pain control using continuous i.m. bupivacaine
infusion plus patient-controlled analgesia compared with epidural analgesia
after major hepatectomy. HPB (Oxford). 2014;16:601–9.
11. Revie EJ, McKeown DW, Wilson JA, Garden OJ, Wigmore SJ. Randomized clinical
trial of local infiltration plus patient-controlled opiate analgesia vs. epidural
analgesia following liver resection surgery. HPB (Oxford). 2012;14:611–8.
12. Kuper M, Gold SJ, Callow C, Quraishi T, King S, Mulreany A, et al.
Intraoperative fluid management guided by oesophageal Doppler
monitoring. BMJ. 2011;342:d3016.
13. Lehmann N, Joshi GP, Dirkmann D, Weiss M, Gulur P, Peters J, et al.
Development and longitudinal validation of the overall benefit of analgesia
score: a simple multi-dimensional quality assessment instrument. Br J
Anaesth. 2010;105:511–8.
14. Mather LE, Chand DH. Cardiotoxicity with modern local anaesthetics: is
there a safer choice? Drugs. 2001;61:333–42.
15. Ventham NT, Hughes M, O’Neill S, Johns N, Brady RR, Wigmore SJ.
Systematic review and meta-analysis of continuous local anaesthetic wound
infiltration versus epidural analgesia for postoperative pain following
abdominal surgery. Br J Surg. 2013;100:1280–9.
16. Tilleul P, Aissou M, Bocquet F, Thiriat N, le Grelle O, Burke MJ, et al. Cost-
effectiveness analysis comparing epidural, patient-controlled intravenous
morphine, and continuous wound infiltration for postoperative pain
management after open abdominal surgery. Br J Anaesth. 2012;108:998–1005.
17. Forastiere E, Sofra M, Giannarelli D, Fabrizi L, Simone G. Effectiveness of
continuous wound infusion of 0.5 % ropivacaine by On-Q pain relief system
for postoperative pain management after open nephrectomy. Br J Anaesth.
2008;101:841–7.
18. Groenwold RH. For the critical reader: questions to ask about randomised
trials. Ned Tijdschr Geneeskd. 2015;159:A9018.
19. Bertoglio S, Fabiani F, Negri PD, Corcione A, Merlo DF, Cafiero F, et al. The
postoperative analgesic efficacy of preperitoneal continuous wound
infusion compared to epidural continuous infusion with local anesthetics
after colorectal cancer surgery: a randomized controlled multicenter study.
Anesth Analg. 2012;115:1442–50.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mungroop et al. Trials  (2015) 16:562 Page 8 of 8
